CHATreg-101

CHATreg-101 is an **autologous regulatory T cell cell therapy** being developed by **CHA Biotech** as an immunomodulatory treatment for **graft-versus-host disease** and autoimmune diseases including **rheumatoid arthritis**, **systemic lupus erythematosus**, and **inflammatory bowel disease**. The product uses a patient's own **regulatory T cells** to suppress pathogenic immune responses and restore immune tolerance, which is the core therapeutic rationale for Treg-based cell therapy in alloimmune and autoimmune disorders. Based on CHA Biotech's pipeline materials, CHATreg-101 is being advanced under Korea's Advanced Regenerative Bio Act framework in a **clinical research and early access** setting, consistent with early-stage clinical development.

Other names

autologous Treg cell therapy